Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced its interim results, with a net profit attributable to shareholders of approximately 2.096 billion yuan, a 16.7% decrease compared to the same period last year.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced its mid-year results for 2026, with operating revenue of approximately 42.091 billion yuan, a year-on-year increase of 0.61%; net profit attributable to company shareholders was approximately 2.096 billion yuan, a year-on-year decrease of 16.7%; basic earnings per share were 1.289 yuan, with a cash dividend distribution of 0.30 yuan per share (tax included). During the reporting period, sales revenue from products such as An Gong Niu Huang Wan, amoxicillin series, cefixime series, Pediatric Qixing Tea, and Kunxian Capsules achieved rapid year-on-year growth; the company actively promoted the national and local collective procurement applications and the layout for the inclusion of essential medicines. During the reporting period, 24 products, including injectable cefotaxime sodium, clindamycin phosphate injection, memantine hydrochloride tablets, and amoxicillin granules, successfully made the list of the first to eighth batches of national organized collective procurement. Subsequently, 19 new specifications, including Xiao Chai Hu granules, were newly included in the "National Essential Medicines List (2026 Edition)"; the company continued to strengthen brand building and established its own brand matrix to amplify the market influence of local brands; it also focused on expanding its investment and cooperation, with hundreds of high-quality products opening cooperation channels at investment conferences to continuously broaden the sales network. In addition, the group expects capital expenditures for 2026 to be approximately 2.152 billion yuan, of which 536 million yuan has already been spent in the first half of 2026 (first half of 2025: 649 million yuan), mainly for the construction of production bases, equipment upgrades, and information system construction.